Wedbush Reiterates Outperform, $423 PT on Intercept (ICPT) Following FDA Panel Backing
Tweet Send to a Friend
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $423 acquisition value on Intercept Pharmaceuticals (NASDAQ: ICPT) after the Gastrointestinal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
